The study points out that different strains of probiotics have different inherent properties, suggesting that the unique ability of GanedenBC30 to survive common conditions that can potentially kill other probiotics before they can have a beneficial effect, such as manufacturing conditions, extreme temperatures, and the harsh gastric environment, may contribute to its ability to support the immune system. Dr. Ken Alibek, M.D., Ph.D., Sc.D., an infectious disease, microbiology, and immunology expert who has studied Bacillus coagulans extensively, believes that the strain may be the most ideal in existence, noting that "no other probiotic has the ability like that of Bacillus coagulans to survive the challenges probiotics face in reaching the intestinal tract where they can do good" and added that "once there, no other strain is as prolific in producing the beneficial by-products responsible for many of the benefits of probiotics."
"This study is another step forward in our understanding of probiotics and the many health benefits they can deliver," said Andrew Lefkowitz, CEO of Ganeden Biotech, which helped fund the study through a research grant and has completed a total of seven clinical trials using GanedenBC30, including trials in immunity, IBS, intestinal gas, Crohn's disease, osteoarthritis, and rheumatoid arthritis. "We will
|SOURCE Ganeden Biotech Inc.|
Copyright©2009 PR Newswire.
All rights reserved